Company Overview

N O V E M B E R 2 0 1 9

Safe Harbor Statement

[ 1 ]

Certain statements in this presentation, including responses to questions, contain or may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,”’ “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning: estimates regarding the annual total addressable global market for our Precision Flow systems, future results of operations, financial position, research and development costs, capital requirements and our needs for additional financing; commercial success and market acceptance of our Precision Flow systems; competitive companies and technologies in our industry; our ability to enhance our Precision Flow systems, expand our indications and develop and commercialize additional products; our business model and strategic plans for our products, technologies and business, including our implementation thereof; our ability to accurately forecast customer demand for our Precision Flow systems and manage our inventory; our ability to expand, manage and maintain our direct sales and marketing organization, and to distribute our Precision Flow systems in markets outside of the United States; our ability to hire and retain our senior management and other highly qualified personnel; our ability to obtain additional financing in the offering to which this presentation relates or future offerings; our ability to commercialize or obtain regulatory approvals for our products, or the effect of delays in commercializing or obtaining regulatory approvals; U.S. Food and Drug Administration or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; our ability to establish and maintain intellectual property protection for our products or avoid claims of infringement; the volatility of the trading price of our common stock; our expectations regarding the use of proceeds from the offering to which this presentation relates; our expectations about market trends; and the other risks described in the “Risk Factors” section of our Annual Report on Form 10-K filed with the Securities and Exchange Commission, or SEC, on March 22, 2019, Part I, “Item 1A. Risk Factors” and in our other filings with the SEC.

The forward-looking statements in this presentation are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this presentation and are subject to a number of known and unknown risks, uncertainties and assumptions. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

A global medical technology company focused on treating patients with respiratory distress

ClinicallyValidated

2.0M+Patients Treated

15K+Installed Base

~$46.8MRevenues*

14% YoY Growth

The only mask-free, clinically validated alternative to current standard of care for the treatment of respiratory distress

ProprietaryHi-VNI®

Technology

[ 2 ] * LTM 9/30/19

Severe Difficulty Breathing –Can’t inhale enough O2

or clear enough CO2

Affects All Ages– pre-term infants, children,

adults

A Large and

Growing Market

THE CAUSES

PneumoniaHeart failure

AsthmaCOPD

… and many other diseases

THE DRIVERS

Aging population

Growing prevalence ofheart failure

Growing prevalence of COPD

Respiratory Distress –

[ 3 ]

$1.5 Billion Global Market –in Current Products, in Current Care Areas

[ 4 ]

1 Suffering from respiratory distress in the US and select international markets who can benefit from Vapotherm technology2 UK, Germany, Brazil, Mexico, Japan, and select markets

CURRENT ADDRESSABLE MARKETS

US Select Ex-US2

Combined over

$1.5BN

CURRENT CARE SETTINGS

12M1

patients suffering respiratory distress

LIMITATIONS

• O2 delivery only• Clinically unproven in

patients with elevated CO2

• 30% patients do not tolerate• High intensity of care• Risks: skin breakdown, lung

injury, etc.

• Sedation often required• Increases clinical risk and cost• Difficulty weaning

Traditional Treatment Modalities Have Limitations

[ 5 ]

INVASIVENESSof Modality

ACUITY of Respiratory Distress

TRADITIONAL STANDARDOF CARE

35 year-old TechnologyOxygen-Based

Therapies

Mechanical VentilationNIPPV

(Non-Invasive Positive Pressure Ventilation)

Hi-VNI® Technology: Attractive Alternative to NIPPV

[ 6 ]

Clinically validated to be AS EFFECTIVE AS NIPPV for spontaneously breathing patients AND:

BETTER Tolerated | EASIER Administration | REDUCED Patient Monitoring Potential

• Appropriate to startat high flows

DE-ESCALATION THERAPY

• No mask-fitting required• Easy to eat / drink / talk• Better tolerated and

more comfortable

NON-OCCLUSIVENASAL CANNULA

• Decreases risk of soft tissue damage

NO POSITIVE PRESSURE

Hi-VNI Technology Redefines the Continuumof Care for Respiratory Distress

[ 7 ]

Increased Acuity Levels of Respiratory Distress

“ ”High velocity nasal insufflation of oxygen is easier to set up than NIPPV. Should this study’s findings be replicated in larger studies, Hi-VNI might replace NIPPV in EDs, intensive care units, and ambulances.

– Feb 2018

Oxygen NIPPV Mechanical Ventilation

TRADITIONAL Treatment

Continuum

NIPPV Mechanical Ventilation

REDEFINED Treatment

Continuum Hi-VNI Technology by Vapotherm

Our Connected, Mobile, Adaptable Precision Flow® Systems

[ 8 ]

Capital Unit

Precision Flow Hi-VNI™ Unit

VapothermTransfer Unit

Electronic Components;Input Gas Controls

Disposables

PATIENT CIRCUIT DELIVERY TUBE

Breathing Gas

Flow Return

Cross-Section of Tubing

Warm waterBreathing Gas

Warm water

Breathing Gas Triple-lumen Delivery Tube

Small-bore Nasal Interfaces and Adapters

Hi-VNI Technology: Breakthrough Solution to Help Avoid Intubation

[ 9 ]

CO2-richdeadspace

Delivers conditioned breathing gas to

patient

Flushes CO2 from respiratory dead space between breaths

High VELOCITY… in an open system

Proper HUMIDIFICATION… delivers adequately conditioned oxygen

OUR SECRET SAUCE

Our Secret Sauce

[ 10 ]

High VELOCITY

… creates efficient flush –even in patients breathing rapidly

0

10

20

30

40

50

60

70

0 20 40 60 80

Velo

city

(m/s

ec)

Volumetric Flow (L/min)

Hi-VNI Technology

ConventionalHigh Flow Oxygen

… allows patient comfort and abilityto tolerate therapy

Proper HUMIDIFICATION

Driven gas stream

Water vapor diffuses through the membrane into gas stream

Gas saturated with vapor at body temperature of circulating water

Compelling Clinical Data

[ 11 ]

A 204-patient, multi-site prospective randomized controlled trial showed Hi-VNI Technologyis a safe and effective alternative to NIPPV for all cause respiratory distress patients

INTUBATION RATESHi-VNI TECHNOLOGY vs. NIPPV

BLOOD CARBON DIOXIDE LEVELS OVER TIME

% Intubated in 72 Hours

Hi-VNI Technology

NIPPV

0 5 10 15 20 25

7%

13%

Non-inferiorto NIPPV inpreventingintubation

0

10

20

30

40

50

60

70

BL 1 Hr 4 Hr

PCO

2 (m

mHg

)

Hi-VNI Technology

NIPPV

Similar decrease in blood CO2 levels

Sample Timepoint

Clinically-Focused Sales Approach

[ 12 ]

100+ personsales organization

US + UKDIRECT

Germany, Brazil, Japan, Mexico

INTERNATIONALDISTRIBUTORS

DIRECT SALES

CLINICAL EDUCATION

NewCustomers

ExistingCustomers

Digital MarketingMedical Education

SALES STRATEGY

Broad Use Today Across Areas ... and Care Givers

[ 13 ]

GROWTH FOCUS Emergency departments

New hospital departments

New areaspre- and post-hospital

Physicians

RespiratoryTherapists

Nurses

HOSPITAL DIRECTORY

Emergency Department

Long Term Acute Care

Intensive Care (ICU)

Pediatric (ICU)

Neonatal (ICU)

US OPPORTUNITY & CURRENT PENETRATION (in blue):

400LTACHs

1,100NICUs

5,000EDs

Pipeline of New Products

[ 14 ]

EnhanceCurrent Portfolio

Market-ExpandingProducts

Oxygen Assist Module

• Simplified/automated adjustments to gas delivery

• Recently completed clinical trial in pre-term infants

Next Gen ProSoft Cannula+

Aerosol Disposable Patient Circuit

• Improved patient comfort• Streamlined workflow of continuous

aerosol medication delivery

Next Gen Hi-VNI Technology Product

• Portable device• Frees from constraint of built-in wall

compressed air

Precision Flow Oxygen Assist Module Overview Automated O2 Module for the Precision Flow Platform

[ 15 ]

Source: Reynolds PR, Miller TL, Volakis LI, et al. Randomized cross-over study of automated oxygen control for preterm infants receiving nasal high flow. Archives of Disease in Childhood - Fetal and Neonatal Edition Published Online First: 21 November 2018.

Time in Target Range:Auto 80% (70-87)

Manual 49% (40-57)

Auto (PF OAM)Manual

p < 0.0001

[ 16 ]

Very Best People Total Customer Focus

Management Team with Proven Track Record

[ 17 ]

MANAGEMENT TEAM

Joe ArmyPresident and CEO

John LandryVP & CFO

Lindsay BeckerVP HR

David BlouinVP US Sales

John CoolidgeVP Operations

Marc DavidsonVP R&D

Jill DoolingVP Strategic Accts

George DunganVP Science and Innovation

Richelle HelmanVP RA/QA

Michael McQueenVP MedED

Gregoire RamadeVP International

Experienced Board

[ 18 ]

Jim LikenChairman

Joe ArmyPresident and CEO

Tony ArnerichInvestor

Bess WeathermanIndependent

Geoff PardoInvestor

Craig ReynoldsIndependent

Neal ArmstrongIndependent

Marina Hahn Independent

Revenue

[ 19 ]

Disposables as % of Revenue

As of September 30, 2019, global installed base of over

15,000 capital units

Disposables revenue driving consistent,

predictable revenue67.3% 67.1% 66.7% 72.3%

2017 2018 3Q18* 3Q19*

$35.6 M$42.4 M

$9.4 M $10.8 M

2017 2018 3Q18 3Q19

19.0%

15.1%

Capital UnitsDisposables

* YTD thru 9/30/18 & 9/30/19

Gross Margins

[ 20 ]

37.2%39.6%

44.0%

38.5%

44.5%

2017 2018 2019* 3Q18 3Q19

Gross Margin Improvement (2017-3Q19):

+730 bps

Additional Gross MarginImprovement from:

1. New products2. Cost reductions3. Increased manufacturing volumes

* YTD thru 9/30/19

3 MONTHS ENDEDSEPTEMBER 30

9 MONTHS ENDEDSEPTEMBER 30

Historical P&L

[ 21 ]

$ Thousands 2018 2019 2018 2019

Total Revenue $9,389 $10,809 $30,691 $35,094

% Growth 19.2% 15.1% 21.8% 14.3%

Gross Profit $3,614 $4,810 $11,954 $15,448

Gross Margin % 38.5% 44.5% 38.9% 44.0%

Sales & Marketing 7,757 9,193 24,331 27,786

% of Revenue 82.6% 85.0% 79.3% 79.2%

G&A 2,804 3,978 7,789 13,389

% of Revenue 29.9% 36.8% 25.4% 38.2%

R&D 1,766 3,280 6,074 9,720

% of Revenue 18.8% 30.3% 19.8% 27.7%

Loss on Disposal of Property & Equipment 17 0 59 0

Total Operating Expenses $12,344 $16,451 $38,253 $50,895

Loss from Operations ($8,730) ($11,641) ($26,299) ($35,447)

Disruptive Hi-VNI TECHNOLOGY for the treatment of respiratory distress

Large global $1.5BN+ MARKET opportunity

Compelling body of CLINICAL DATA and an FDA de novo grant of expanded indications for use

Direct SALES FORCE in US + UK and experienced international DISTRIBUTORS, supported by clinical team

Robust and growing IP PATENT PORTFOLIO

Recurring REVENUE MODEL with high visibility on our disposables utilization

Experienced management TEAM, board and investors

Building Long Term, Sustainable Competitive Advantage

[ 22 ]